Alternatives to Metformin for Type 2 Diabetes

Primary Alternative Agents Based on Comorbidities

The American Diabetes Association recommends SGLT2 inhibitors as the preferred first-line alternative for most patients with type 2 diabetes, particularly those with cardiovascular disease, heart failure, or chronic kidney disease (eGFR ≥20 ml/min/1.73 m²), based on their proven benefits in reducing cardiovascular events, heart failure, and kidney disease progression 1, 2
SGLT2 inhibitors should be used in most patients with type 2 diabetes and CKD with eGFR ≥20 ml/min/1.73 m², independent of HbA1c or need for additional glucose lowering, as they reduce CKD progression, heart failure, and atherosclerotic cardiovascular disease risk independent of their glucose-lowering effects 1
For patients with established cardiovascular disease, SGLT2 inhibitors with proven cardiovascular benefit should be prioritized to reduce major adverse cardiovascular events, according to the American College of Cardiology 2
The European Association for the Study of Diabetes recommends avoiding SGLT2 inhibitors in patients with history of diabetic ketoacidosis, recurrent genital candidiasis, amputation, severe peripheral arterial disease, or diabetic foot ulcers 2
GLP-1 receptor agonists with demonstrated cardiovascular benefit are recommended for patients with established cardiovascular disease, particularly those requiring significant weight loss due to their substantial weight reduction effects, as suggested by the American Heart Association 2

DPP-4 inhibitors can be considered as add-on therapy or alternatives for patients with type 2 diabetes, according to the American Diabetes Association 3, 4
Basal insulin should be initiated without delay for severe hyperglycemia (HbA1c ≥10% or blood glucose ≥300 mg/dL), especially with catabolic features, as recommended by the Endocrine Society 4, 2

Assess renal function (eGFR) before initiating any alternative agent, as this determines appropriate drug selection and dosing, according to the National Kidney Foundation 2
Regular HbA1c monitoring every 3 months is essential to assess effectiveness of alternative therapy, as suggested by the American Diabetes Association 4, 2

Delaying insulin therapy when hyperglycemia is severe can lead to poor outcomes; institute insulin without delay in patients not achieving glycemic goals, according to the American Association of Clinical Endocrinologists 2
Overlooking the cardiovascular and renal benefits of SGLT2 inhibitors and GLP-1 receptor agonists results in suboptimal treatment selection, as noted by the European Society of Cardiology 1, 2